From the 1st December the infliximab biosimilar Inflectra™ will be listed on the PBS for the same indications that apply to its comparator drug Remicade™. The PBS update shows that Inflectra™ and its originator biologic is marked as equivalent on the Schedule of Pharmaceutical Benefits (‘a’ flagged), for the purposes of substitution by a pharmacist ...
Infliximab biosimilar gets PBS listing
By Nicola Garrett
30 Nov 2015